Cargando…

Association between Helicobacter pylori infection and mortality risk in prostate cancer patients receiving androgen deprivation therapy: A real‐world evidence study

PURPOSE: Helicobacter pylori (H. pylori) is a major risk factor for gastric cancer and may affect androgen activity in men. The association between H. pylori and androgen deprivation therapy (ADT) in patients with prostate cancer (PCa) remains unclear. METHODS: This retrospective cohort study linked...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jui‐Ming, Wu, Chun‐Te, Hsu, Ren‐Jun, Hsu, Wen‐Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607261/
https://www.ncbi.nlm.nih.gov/pubmed/34590436
http://dx.doi.org/10.1002/cam4.4318
_version_ 1784602528879476736
author Liu, Jui‐Ming
Wu, Chun‐Te
Hsu, Ren‐Jun
Hsu, Wen‐Lin
author_facet Liu, Jui‐Ming
Wu, Chun‐Te
Hsu, Ren‐Jun
Hsu, Wen‐Lin
author_sort Liu, Jui‐Ming
collection PubMed
description PURPOSE: Helicobacter pylori (H. pylori) is a major risk factor for gastric cancer and may affect androgen activity in men. The association between H. pylori and androgen deprivation therapy (ADT) in patients with prostate cancer (PCa) remains unclear. METHODS: This retrospective cohort study linked National Health Insurance (NHI) data to Taiwan Cancer Registry (TCR) and Taiwan Death Registry (TDR) between 1995 and 2016. PCa patients who received ADT were classified into H. pylori infection and non‐H. pylori infection groups. The outcomes were overall mortality, prostate cancer‐specific mortality, and castration‐resistant prostate cancer (CRPC). Propensity score matching was adopted for the primary analysis and inverse probability of treatment weighting (IPTW) was used for the sensitivity analysis. RESULTS: Of the 62,014 selected PCa patients, 23,701 received ADT, of whom 3516 had H. pylori infections and 20,185 did not. After matching, there were 3022 patients in the H. pylori infection group and 6044 patients in the non‐H. pylori infection group. The mean follow‐up period for the matched cohort was 4.8 years. Compared to the non‐H. pylori group, the H. pylori group was significantly associated with decreased risks of all‐cause mortality (hazard ratio [HR] 0.90; 95% confidence interval [CI] 0.84–0.96) and prostate cancer‐specific mortality (HR 0.88; 95% CI 0.81–0.95) in the matched analysis. CONCLUSIONS: H. pylori infection was associated with a reduced risk of mortality in PCa patients receiving ADT.
format Online
Article
Text
id pubmed-8607261
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-86072612021-11-29 Association between Helicobacter pylori infection and mortality risk in prostate cancer patients receiving androgen deprivation therapy: A real‐world evidence study Liu, Jui‐Ming Wu, Chun‐Te Hsu, Ren‐Jun Hsu, Wen‐Lin Cancer Med Cancer Prevention PURPOSE: Helicobacter pylori (H. pylori) is a major risk factor for gastric cancer and may affect androgen activity in men. The association between H. pylori and androgen deprivation therapy (ADT) in patients with prostate cancer (PCa) remains unclear. METHODS: This retrospective cohort study linked National Health Insurance (NHI) data to Taiwan Cancer Registry (TCR) and Taiwan Death Registry (TDR) between 1995 and 2016. PCa patients who received ADT were classified into H. pylori infection and non‐H. pylori infection groups. The outcomes were overall mortality, prostate cancer‐specific mortality, and castration‐resistant prostate cancer (CRPC). Propensity score matching was adopted for the primary analysis and inverse probability of treatment weighting (IPTW) was used for the sensitivity analysis. RESULTS: Of the 62,014 selected PCa patients, 23,701 received ADT, of whom 3516 had H. pylori infections and 20,185 did not. After matching, there were 3022 patients in the H. pylori infection group and 6044 patients in the non‐H. pylori infection group. The mean follow‐up period for the matched cohort was 4.8 years. Compared to the non‐H. pylori group, the H. pylori group was significantly associated with decreased risks of all‐cause mortality (hazard ratio [HR] 0.90; 95% confidence interval [CI] 0.84–0.96) and prostate cancer‐specific mortality (HR 0.88; 95% CI 0.81–0.95) in the matched analysis. CONCLUSIONS: H. pylori infection was associated with a reduced risk of mortality in PCa patients receiving ADT. John Wiley and Sons Inc. 2021-09-29 /pmc/articles/PMC8607261/ /pubmed/34590436 http://dx.doi.org/10.1002/cam4.4318 Text en © 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Cancer Prevention
Liu, Jui‐Ming
Wu, Chun‐Te
Hsu, Ren‐Jun
Hsu, Wen‐Lin
Association between Helicobacter pylori infection and mortality risk in prostate cancer patients receiving androgen deprivation therapy: A real‐world evidence study
title Association between Helicobacter pylori infection and mortality risk in prostate cancer patients receiving androgen deprivation therapy: A real‐world evidence study
title_full Association between Helicobacter pylori infection and mortality risk in prostate cancer patients receiving androgen deprivation therapy: A real‐world evidence study
title_fullStr Association between Helicobacter pylori infection and mortality risk in prostate cancer patients receiving androgen deprivation therapy: A real‐world evidence study
title_full_unstemmed Association between Helicobacter pylori infection and mortality risk in prostate cancer patients receiving androgen deprivation therapy: A real‐world evidence study
title_short Association between Helicobacter pylori infection and mortality risk in prostate cancer patients receiving androgen deprivation therapy: A real‐world evidence study
title_sort association between helicobacter pylori infection and mortality risk in prostate cancer patients receiving androgen deprivation therapy: a real‐world evidence study
topic Cancer Prevention
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607261/
https://www.ncbi.nlm.nih.gov/pubmed/34590436
http://dx.doi.org/10.1002/cam4.4318
work_keys_str_mv AT liujuiming associationbetweenhelicobacterpyloriinfectionandmortalityriskinprostatecancerpatientsreceivingandrogendeprivationtherapyarealworldevidencestudy
AT wuchunte associationbetweenhelicobacterpyloriinfectionandmortalityriskinprostatecancerpatientsreceivingandrogendeprivationtherapyarealworldevidencestudy
AT hsurenjun associationbetweenhelicobacterpyloriinfectionandmortalityriskinprostatecancerpatientsreceivingandrogendeprivationtherapyarealworldevidencestudy
AT hsuwenlin associationbetweenhelicobacterpyloriinfectionandmortalityriskinprostatecancerpatientsreceivingandrogendeprivationtherapyarealworldevidencestudy